French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.
Bridgestone Corporation's shares have delivered a robust 33% total return to shareholders over the past year, outpacing its recent short-term volatility. This performance prompts a closer look at whether the tire giant's current valuation still offers room for growth or if the market has already priced in its future prospects.
Shares of building technologies giant Johnson Controls International have surged over 60% in the past year, dramatically outperforming the broader market. As the stock hovers near $123, investors are grappling with a critical question: does the current price reflect the company's true value, or has momentum outpaced fundamentals? A deep dive into valuation metrics suggests caution may be warranted.
Following a significant boardroom reshuffle and a strategic overhaul of its sales divisions, Japanese paper giant Hokuetsu (TSE:3865) finds itself at a critical juncture. With its stock showing signs of undervaluation against a backdrop of volatile returns, investors are weighing the potential of its new direction against the risks of execution.
Once a high-flying AI discovery platform, AbCellera Biologics is navigating a critical transition to a clinical-stage biotech. With a fortified balance sheet and key Phase 1 readouts on the horizon, some investors see a compelling, albeit risky, turnaround story taking shape.
Polaris Inc. shares have surged over 55% in the past year, but a recent pullback has investors questioning whether the powersports leader remains a buy. Conflicting signals from valuation models paint a complex picture for the iconic brand.
Brendan Banfield has been convicted of the aggravated murder of his wife and a stranger lured through a fake BDSM encounter, a plot allegedly orchestrated with the family's live-in nanny who testified against him.
Cirrus Logic (CRUS) shares have surged over 31% in the past year, prompting investors to question whether the current price fully reflects the company's prospects. A deep dive into valuation metrics suggests the semiconductor stock may be trading at a significant premium.
PPG Industries' stock has climbed over 20% this quarter following robust 2025 results and an upgraded 2026 earnings forecast. While analysts cheer the company's strategic execution, questions linger about valuation and macroeconomic headwinds.
Shares of GE Vernova (GEV) have surged over 100% in the past year, closing near $726. As the energy transition play captivates the market, analysts are divided on whether its valuation still offers room to run or signals a peak.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
Qualcomm shares have retreated over 12% this year, prompting a fresh debate on whether the chipmaker's long-term AI and edge computing narrative justifies its current valuation.
Amidst a resilient market backdrop, we spotlight three U.S. stocks trading significantly below their estimated intrinsic value, offering potential for investors willing to navigate current volatility.
Alliance Resource Partners (ARLP) posted a significant jump in fourth-quarter profit, driven by cost controls and investment gains, even as coal revenue softened. The partnership issued 2026 guidance pointing to robust contract coverage and a growing oil & gas royalty segment, while navigating challenges at a key Appalachian mine.
A new economic report finds that while inflation has cooled, recent tariff policies have kept prices higher than they otherwise would be, as the Supreme Court weighs the legality of the measures.
Amid a sharp pullback in gold and silver prices, NovaGold Chairman Thomas Kaplan remains steadfastly bullish, telling Business Insider he views the volatility as a temporary setback on a path to record highs.
Taiwan Semiconductor Manufacturing Company (TSMC), commanding over 70% of the advanced chip foundry market, is accelerating its U.S. manufacturing footprint amid shifting trade policies and sustained explosive financial growth, solidifying its indispensable role.
A discounted cash flow analysis suggests Savaria Corporation's stock may be trading significantly below its intrinsic value, presenting a potential opportunity for investors. However, experts caution that valuation models are only one piece of the investment puzzle.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
